148 related articles for article (PubMed ID: 12463730)
21. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Choi HY; Lim HS; Kim YH; Jeon HS; Kim MJ; Lee SH; Jung JH; Lee YK; Kim HJ; Bae KS
Curr Med Res Opin; 2015 Feb; 31(2):229-41. PubMed ID: 25350224
[TBL] [Abstract][Full Text] [Related]
22. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.
Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Quinson AM; Haertter S
J Clin Pharmacol; 2017 Oct; 57(10):1305-1314. PubMed ID: 28513969
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.
Birmingham BK; Swan SK; Puchalski T; Mitchell P; Azumaya C; Zalikowski J; Wang Y
Clin Drug Investig; 2013 Apr; 33(4):233-41. PubMed ID: 23494963
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.
Jindal D; Tandon M; Sharma S; Pillai KK
Eur J Clin Pharmacol; 2005 Oct; 61(9):621-5. PubMed ID: 16133549
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
Simonson SG; Martin PD; Mitchell P; Schneck DW; Lasseter KC; Warwick MJ
Eur J Clin Pharmacol; 2003 Feb; 58(10):669-75. PubMed ID: 12610743
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
[TBL] [Abstract][Full Text] [Related]
28. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
Stopfer P; Giessmann T; Hohl K; Hutzel S; Schmidt S; Gansser D; Ishiguro N; Taub ME; Sharma A; Ebner T; Müller F
Br J Clin Pharmacol; 2018 Sep; 84(9):1941-1949. PubMed ID: 29665130
[TBL] [Abstract][Full Text] [Related]
29. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
Zussman BD; Kelly J; Murdoch RD; Clark DJ; Mbchb ; Schubert C; Collie H
Clin Ther; 2001 Jun; 23(6):921-31. PubMed ID: 11440291
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study.
Son M; Kim Y; Lee D; Roh H; Son H; Guk J; Jang SB; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1147-58. PubMed ID: 24998012
[TBL] [Abstract][Full Text] [Related]
31. Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study.
Liuni A; Luca MC; Gori T; Parker JD
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H153-8. PubMed ID: 22003053
[TBL] [Abstract][Full Text] [Related]
32. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
Schwartz JI; De Smet M; Larson PJ; Verbesselt R; Ebel DL; Lins R; Lens S; Porras AG; Gertz BJ
J Clin Pharmacol; 2001 Jan; 41(1):107-12. PubMed ID: 11144988
[TBL] [Abstract][Full Text] [Related]
33. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.
Vousden M; Allen A; Lewis A; Ehren N
Chemotherapy; 1999; 45(6):485-90. PubMed ID: 10567779
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.
Bologa R; Levine D; Parker T; Gordon B; Lanto A; Cheigh J; Stenzel K; Rubin A
Clin Nephrol; 2009 Dec; 72(6):437-41. PubMed ID: 19954720
[TBL] [Abstract][Full Text] [Related]
35. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).
ter Avest E; Abbink EJ; Holewijn S; de Graaf J; Tack CJ; Stalenhoef AF
Curr Med Res Opin; 2005 Sep; 21(9):1469-76. PubMed ID: 16197666
[TBL] [Abstract][Full Text] [Related]
36. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
37. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Gidal BE; Mintzer S; Schwab M; Schutz R; Kharidia J; Blum D; Grinnell T; Sunkaraneni S
Epilepsy Res; 2017 Sep; 135():64-70. PubMed ID: 28624574
[TBL] [Abstract][Full Text] [Related]
38. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Weber P; Lettieri JT; Kaiser L; Mazzu AL
Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
[TBL] [Abstract][Full Text] [Related]
39. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
Kang WY; Kim EH; Seong SJ; Gwon MR; Yang DH; Kim HJ; Lim MS; Lee HW; Yoon YR
Int J Clin Pharmacol Ther; 2016 Dec; 54(12):992-1003. PubMed ID: 27668695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
